NCT00097331View on ClinicalTrials.gov

Three Months Treatment With SB683699 In Patients With Relapsing Multiple Sclerosis

PHASE2CompletedINTERVENTIONAL
Enrollment

261

Participants

Timeline

Start Date

September 30, 2004

Primary Completion Date

July 31, 2006

Study Completion Date

July 31, 2006

Conditions
Multiple Sclerosis, Relapsing-Remitting
Interventions
DRUG

SB683699

Trial Locations (11)

1200

GSK Investigational Site, Brussels

4557

GSK Investigational Site, Fraiture En Condroz

20099

GSK Investigational Site, Hamburg

22087

GSK Investigational Site, Hamburg

29010

GSK Investigational Site, Málaga

117049

GSK Investigational Site, Moscow

125367

GSK Investigational Site, Moscow

197022

GSK Investigational Site, Saint Petersburg

80-308

GSK Investigational Site, Polanki

60-479

GSK Investigational Site, Poznan

02-957

GSK Investigational Site, Warsaw

Sponsors

Lead Sponsor

GlaxoSmithKline
All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY